Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2407546121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Jung-Hyun Choi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Goodman Cancer Institute, McGill University, Montreal, QC H3A 1A3, Canada. Hauptthemen laut MEDLINE: Metformin, Fragile X Syndrome, Fragile X Messenger Ribonucleoprotein 1. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Government | Canadian Institutes of Health Research (CIHR), National Research Foundation of Korea (NRF), FRAXA Research Foundation (FRF).
Abstract (Originalsprache)
Fragile X syndrome (FXS) is the most common genetic cause of autism spectrum disorder engendered by transcriptional silencing of the fragile X messenger ribonucleoprotein 1 ( FMR1 ) gene. Given the early onset of behavioral and molecular changes, it is imperative to know the optimal timing for therapeutic intervention. Case reports documented benefits of metformin treatment in FXS children between 2 and 14 y old. In this study, we administered metformin from birth to Fmr1 −/y mice which corrected up-regulated mitogen-2 activated protein kinase/extracellular signal-regulated kinase and mammalian/mechanistic target of rapamycin complex 1 signaling pathways and specific synaptic mRNA-binding targets of FMRP. Metformin rescued increased number of calls in ultrasonic vocalization and repetitive behavior in Fmr1 −/y mice. Our findings demonstrate that in mice, early-in-life metformin intervention is effective in treating FXS pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Goodman Cancer Institute, McGill University, Montreal, QC H3A 1A3, Canada.
ORCID-Profile: Jung-Hyun Choi, Laura Marsal-García, Eve Peraldi, Ilse Gantois, Nahum Sonenberg
Förderung
- Canadian Government | Canadian Institutes of Health Research (CIHR)
- National Research Foundation of Korea (NRF)
- FRAXA Research Foundation (FRF)
Zitieren
APA
Choi, J. H., Marsal-García, L., Peraldi, E., Walters, C., Huang, Z., Gantois, I., & Sonenberg, N. (2024). Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2407546121
Vancouver
Choi JH, Marsal-García L, Peraldi E, Walters C, Huang Z, Gantois I, et al. Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2407546121
BibTeX
@article{Choi2024,
author = {Choi, Jung-Hyun and Marsal-García, Laura and Peraldi, Eve and Walters, Caleb and Huang, Ziying and Gantois, Ilse and Sonenberg, Nahum},
title = {Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2407546121}
}
EUVIMED